Skip to main content
. 2021 May 5;12(13):3877–3886. doi: 10.7150/jca.52315

Figure 3.

Figure 3

miRNAs mediate CD47 expression in VES-treated HeLa cancer cells. (A) HeLa cancer cells were treated with 5, 7.5 and 10 µg/mL VES for 3 h. miRNA-155 and miRNA-133 were examined via quantitative real-time PCR. After the cells were treated with VES for 6 h, miRNA-326 was measured. (B) After 30 h of transfection with the inhibitors of miRNA-133 and miRNA-326 and exposure of the cells to 7.5 µg/mL VES for 24 h, CD47 expression was examined via immunoblotting. After miRNA-155 siRNA-transfected cells were treated with 10 µg/mL VES for 24 h, CD47 level was measured. The data are representative of at least 3 independent experiments. *P ≤ 0.05 compared with control.